# Veerhealth Care (NSE: VEERHEALTH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VEERHEALTH · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹58 Cr, it ranks 2986th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 1.8% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹17 Cr (+198.2% year on year) and net profit −₹0 Cr, on a standalone basis. Promoters held 31.91% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹58 Cr |
| ROE | 1.8% (FY25) |
| ROCE | 2.6% (FY25) |
| Debt to equity | 0.22 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹17 Cr | +198.2% | −₹0 Cr | — | −₹0.18 |
| Q3 FY26 | ₹7 Cr | +89.1% | ₹0 Cr | +471.4% | ₹0.20 |
| Q2 FY26 | ₹4 Cr | −22.7% | ₹0 Cr | −16.7% | ₹0.13 |
| Q1 FY26 | ₹4 Cr | +118.0% | ₹0 Cr | +100.0% | ₹0.12 |
| Q4 FY25 | ₹6 Cr | +66.8% | −₹0 Cr | — | −₹0.05 |
| Q3 FY25 | ₹4 Cr | +33.8% | ₹0 Cr | −63.2% | ₹0.04 |
| Q2 FY25 | ₹5 Cr | +34.5% | ₹0 Cr | −23.1% | ₹0.15 |
| Q1 FY25 | ₹2 Cr | −42.5% | ₹0 Cr | −64.7% | ₹0.06 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹17 Cr | ₹0 Cr |
| FY24 | ₹13 Cr | ₹0 Cr |
| FY23 | ₹13 Cr | ₹2 Cr |
| FY22 | ₹10 Cr | −₹0 Cr |
| FY21 | ₹11 Cr | ₹0 Cr |
| FY20 | ₹12 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 31.91%
- Non-institutions: 68.09%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Samrat Pharma](https://app.pivotnow.in/stock/SAMRATPH) | — | ₹61 Cr | — | — |
| [Royal Sense](https://app.pivotnow.in/stock/ROYAL) | — | ₹59 Cr | — | — |
| [Bacil Pharma](https://app.pivotnow.in/stock/BACPHAR) | — | ₹58 Cr | — | — |
| [Constronics Inf](https://app.pivotnow.in/stock/CONSTRONIC) | — | ₹57 Cr | — | — |
| [Kabra Drugs](https://app.pivotnow.in/stock/KABRADG) | — | ₹56 Cr | — | — |
| [Bandaram Pharma](https://app.pivotnow.in/stock/BANDARAM) | — | ₹53 Cr | — | — |

## Questions and answers

### What is the market cap of Veerhealth Care?

Veerhealth Care's market capitalisation is ₹58 Cr (₹58 Cr) at the 22 Oct 2026 close, ranking 2986th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Veerhealth Care?

Return on equity was 1.8% in FY25 and return on capital employed was 2.6% in FY25 (standalone figures).

### Is Veerhealth Care a debt-free company?

No. Veerhealth Care's debt-to-equity ratio was 0.22 in FY25, with total debt of ₹4 Cr.

### What were Veerhealth Care's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Veerhealth Care reported revenue of ₹17 Cr, +198.2% year on year, and net profit of −₹0 Cr.

### What is the shareholding pattern of Veerhealth Care?

As of 30 Jun 2026: promoters 31.91%, non-institutions 68.09%.

### Who are Veerhealth Care's competitors?

The listed Pharma & Healthcare companies closest to Veerhealth Care by market cap are Samrat Pharma, Royal Sense, Bacil Pharma, Constronics Inf, Kabra Drugs and Bandaram Pharma.

### Is Veerhealth Care a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Veerhealth Care's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VEERHEALTH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.